Enable Injections wins CE mark for enFuse drug delivery device
March 25, 2025
Enable Injections announced today that it received CE mark approval for its EnFuse syringe transfer system for drug delivery.
Enable Injections announced today that it received CE mark approval for its EnFuse syringe transfer system for drug delivery.
A consortium of Austrian research groups from the University of Vienna, MedUni Vienna and Technikum Wien, together with company partner DOC Medikus GmbH, has developed an innovative bioanalytical test system for radiopharmaceutical drug candidates for cancer diagnosis and therapy.
SCOTTSDALE, Ariz., March 20, 2025 /PRNewswire/ — Anuncia Medical, Inc. (“Anuncia”), a pioneering company in CSF management and neurocritical care, has received Breakthrough Device Designation from the FDA for its ReFlow® EVD, an innovative solution for external ventricular drains (EVDs) used to manage brain swelling and elevated intracranial pressure.
Sibel Health announced today that it closed a $30 million equity financing and earned its seventh FDA 510(k) clearance.
GE HealthCare (Nasdaq: GEHC) announced today that it launched its Invenia automated breast ultrasound (ABUS) premium offering.
Blood glucose is usually measured using invasive methods involving pricking small needles into the skin. But people suffering from diabetes have to test their glucose levels many times a day. This repeated use of needles is inconvenient and can increase the risk of potential infections.
A new technique has enabled ultra-powerful magnetic resonance imaging (MRI) scanners to identify tiny differences in patients’ brains that cause treatment-resistant epilepsy. In the first study to use this approach, it has allowed doctors at Addenbrooke’s Hospital, Cambridge, to offer the patients surgery to cure their condition.
FRANKLIN LAKES, N.J., March 20, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption (IDE) clinical trial intended to advance BD’s efforts to achieve Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in decreasing capsular contracture (CC) recurrence during breast revision surgery.
Medtronic (NYSE:MDT) today announced real-world data supporting the use of its smart insulin pen and CGM sensor combination.
Cardiac Dimensions announced today that it closed an oversubscribed Series E financing round worth $53 million.